NewEdge Advisors LLC Has $4.11 Million Position in Boston Scientific Corporation $BSX

NewEdge Advisors LLC cut its position in shares of Boston Scientific Corporation (NYSE:BSX) by 29.6% in the first quarter, Holdings Channel reports. The institutional investor owned 65,461 shares of the medical equipment provider’s stock after selling 27,583 shares during the period. NewEdge Advisors LLC’s holdings in Boston Scientific were worth $4,108,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Outfitters Financial LLC raised its holdings in shares of Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock valued at $2,291,000 after purchasing an additional 110 shares during the last quarter. Natural Investments LLC grew its position in Boston Scientific by 2.9% in the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after purchasing an additional 112 shares in the last quarter. Patton Fund Management Inc. increased its stake in Boston Scientific by 5.5% in the 4th quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider’s stock valued at $217,000 after buying an additional 118 shares during the last quarter. Bridgewater Advisors Inc. increased its stake in Boston Scientific by 1.2% in the 4th quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider’s stock valued at $921,000 after buying an additional 123 shares during the last quarter. Finally, CYBER HORNET ETFs LLC lifted its position in Boston Scientific by 3.4% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after buying an additional 132 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BSX. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a report on Thursday, May 28th. Mizuho lowered their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Truist Financial dropped their price objective on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. TD Cowen lowered their target price on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, BTIG Research dropped their price target on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 29th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have purchased 204,322 shares of company stock worth $9,939,221. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 0.4%

BSX stock opened at $51.40 on Thursday. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The business’s 50 day simple moving average is $45.94 and its 200 day simple moving average is $59.69. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $74.49 billion, a PE ratio of 20.81, a PEG ratio of 1.12 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the firm posted $0.75 EPS. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has authorized a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.